Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 301–400 of 1,001
Baumann, D., Hägele, T., Mochayedi, J., Drebant, J., Vent, C., Blobner, S., Noll, J. H., Nickel, I., Schumacher, C., Boos, S. L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15979-2 · Cited by 76
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 74
Li, F., Deng, L., Jackson, K. R., Talukder, A. H., Katailiha, A. S., Bradley, S. D., Zou, Q., Chen, C., Huo, C., Chiu, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002531 · Cited by 82
CD4 + T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses
Bawden, E., Wagner, T., Schröder, J., Effern, M., Hinze, D., Newland, L., Attrill, G. H., Lee, A. R., Engel, S., Freestone, D., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi9517 · Cited by 82
“F10 cells ( 57 ).”
Correlates of immune and clinical activity of novel cancer vaccines
van der Burg, S. H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.04.001 · Cited by 77
Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma
Zheng, C., Snow, B. E., Elia, A. J., Nechanitzky, R., Dominguez-Brauer, C., Liu, S., Tong, Y., Cox, M. A., Focaccia, E., Wakeham, A. C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00624-w · Cited by 75
“4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’ 35 .”
BackgroundCancer Vaccines: Promising Therapeutics or an Unattainable Dream
Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 80
Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors
Ye, T., Li, F., Ma, G., & Wei, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113927 · Cited by 76
mRNA: A promising platform for cancer immunotherapy
Kong, B., Kim, Y., Kim, E. H., Suk, J. S., & Yang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114993 · Cited by 88
Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
Kumai, T., Lee, S., Cho, H.-I., Sultan, H., Kobayashi, H., Harabuchi, Y., & Celis, E. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0194 · Cited by 79
“Most immunogenic mutation-derived neoepitopes that eradicated tumors were recognized by HTLs (6).”
Neoantigens encoded in the cancer genome
Schumacher, T. N., & Hacohen, N. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.07.005 · Cited by 81
P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy
Li, W., Jing, Z., Wang, S., Li, Q., Xing, Y., Shi, H., Li, S., & Hong, Z. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120726 · Cited by 75
Beck, J. D., Diken, M., Suchan, M., Streuber, M., Diken, E., KOLB, L. D., Allnoch, L., Vascotto, F., Peters, D., Beißert, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.013 · Cited by 78
Self-citationMHC class II restricted neoantigen: A promising target in tumor immunotherapy
Sun, Z., Chen, F., Meng, F., Wei, J., & Liu, B. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.039 · Cited by 79
A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8+ T Cell Epitopes
He, X., Zhou, S., Huang, W., Seffouh, A., Mabrouk, M. T., Morgan, M. T., Ortega, J., Abrams, S. I., & Lovell, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.0c07680 · Cited by 74
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 78
“In addition, melanoma, colon and breast cancer lesions were all enriched for mutations predicted to bind MHC-II molecules [304], and this was recently demonstrated for 6 cancer cell lines by the analysis of MHC-II ligandome using a proteomics approach [305].”
MethodActivating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response
Ruf, B., Catania, V. V., Wabitsch, S., Ma, C., Diggs, L. P., Zhang, Q., Heinrich, B., Subramanyam, V., Cui, L. L., Pouzolles, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0925 · Cited by 74
“The B16F10-GFPþLUC tumor cells express luciferase, which allowed us to monitor tumor burden using a noninvasive imaging assay (19).”
MethodDolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premlal, A. L. R., Greenbaum, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164258 · Cited by 75
“Blockade of PD-1 reliable due to the open structure of the MHC II binding groove, which accommodates peptides of varying lengths (69, 70).”
BackgroundSelf-citationGEP- NETS UPDATE: Genetics of neuroendocrine tumors
Crona, J., & Skogseid, B. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0972 · Cited by 85
Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer
Knocke, S., Fleischmann-Mundt, B., Saborowski, M., Manns, M. P., Kühnel, F., Wirth, T. C., & Woller, N. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.086 · Cited by 75
Evolution of MHC-based technologies used for detection of antigen-responsive T cells
Bentzen, A. K., & Hadrup, S. R. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1971-5 · Cited by 83
“Antigen-responsive CD4 T cells are believed to play a significant role in tumor-cell recognition [33, 34] and development of autoimmune diseases [35, 36].”
BackgroundBeausang, J. F., Wheeler, A. J., Chan, N. H., Hanft, V. R., Dirbas, F. M., Jeffrey, S. S., & Quake, S. R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713863114 · Cited by 74
“CD4 T cells may also be tumor-reactive (45, 46), with 0.”
BackgroundNitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies
Hays, E., & Bonavida, B. (2019) · Antioxidants · doi:10.3390/antiox8090407 · Cited by 74
“Downregulation or mutation of MHCs and decreased antigen presentation [38]”
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
Roy, D. G., Geoffroy, K., Marguerie, M., Khan, S., Martin, N. T., Kmiecik, J., Bobbala, D., Aitken, A. S., de Souza, C. T., Stephenson, K. B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22929-z · Cited by 77
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Takazawa, M., Ohara, O., et al. (2017) · Cancer Science · doi:10.1111/cas.13131 · Cited by 73
Epigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 73
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68
“Furthermore, neoantigen-specific CD4 + T cells that may be responsive to immunotherapy have been observed in cancer patients (20-23), and thus robust activation of tumor antigen specific CD4 + T cells is likely to be important for optimal therapeutic efficacy.”
BackgroundKreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 81
Mutanome directed cancer immunotherapy
Vormehr, M., Diken, M., Boegel, S., Kreiter, S., Türeci, Ÿ., & Şahin, U. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.001 · Cited by 70
Self-citationZahm, C. D., Colluru, V. T., & McNeel, D. G. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0374 · Cited by 68
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
Ott, P. A., & Wu, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1357 · Cited by 72
“In a separate study, neoantigen-directed RNA vaccines targeting MHC Class II neoepitopes mediated tumor regression and infiltration with both CD8+ and CD4+ T cells in melanoma, colon carcinoma, and breast cancer models (39).”
BackgroundBioinformatics for Cancer Immunotherapy
Holtsträter, C., Schrörs, B., Bukur, T., & Löwer, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0327-7_1 · Cited by 66
Self-citationCD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
Richardson, J. R., Schöllhorn, A., Gouttefangeas, C., & Schuhmacher, J. (2021) · Cancers · doi:10.3390/cancers13040596 · Cited by 70
Genetic epidemiology of melanoma
Ribero, S., Glass, D., & Bataille, V. (2016) · European Journal of Dermatology · doi:10.1684/ejd.2016.2787 · Cited by 64
Investigation of charge ratio variation in mRNA – DEAE-dextran polyplex delivery systems
Siewert, C., Haas, H., Nawroth, T., Ziller, A., Nogueira, S. S., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Radulescu, A., Bates, F., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.020 · Cited by 63
Zeng, H., & Gifford, D. K. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.004 · Cited by 67
“Understanding what peptides will be displayed given a disease state is crucial information for developing peptide-based vaccines and therapeutics(Kreiter et al., 2015; Ott et al., 2017; 2017; Verdegaal et al., 2016).”
BackgroundZhang, X., Qi, Y., Zhang, Q., & Liu, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109542 · Cited by 62
Lei, X., Ou, Z., Yang, Z., Zhong, J., Zhu, Y., Tian, J., Wu, J., Deng, H., Lin, X., Yu, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2487 · Cited by 68
“Enzyme-linked ImmunoSpot assay Single-cell suspensions were generated from harvested PDX tumors using a previously described method to analyze tumor-infiltrating T cells (25); cultures were incubated overnight to remove live cancer cells via adhesion to plastic.”
MethodcaAtlas: An immunopeptidome atlas of human cancer
Yi, X., Liao, Y., Wen, B., Li, K., Dou, Y., Savage, S. R., & Zhang, B. (2021) · iScience · doi:10.1016/j.isci.2021.103107 · Cited by 63
The current landscape of immunotherapy for pediatric brain tumors
Hwang, E. I., Sayour, E. J., Flores, C. T., Grant, G. A., Wechsler‐Reya, R. J., Hoang-Minh, L., Kieran, M. W., Salcido, J., Prins, R. M., Figg, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00319-0 · Cited by 73
Lei, X., Lin, H., Wang, J., Ou, Z., Ruan, Y., Sadagopan, A., Chen, W., Xie, S., Chen, B., Li, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31417-x · Cited by 66
Sources of Cancer Neoantigens beyond Single-Nucleotide Variants
Capietto, A.-H., Hoshyar, R., & Delamarre, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710131 · Cited by 69
“However, specific T cell responses can vary with neoantigen-based therapies [35,166], and some sources of neoantigen may have limited platform options.”
BackgroundTANTIGEN: a comprehensive database of tumor T cell antigens
Olsen, L. R., Tongchusak, S., Lin, H., Reinherz, E. L., Brusić, V., & Zhang, G. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1978-y · Cited by 70
Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity
Mastria, E. M., Cai, L. Y., Kan, M. J., Li, X., Schaal, J. L., Fiering, S., Gunn, M. D., Dewhirst, M. W., Nair, S. K., & Chilkoti, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.021 · Cited by 65
Characterizing neoantigens for personalized cancer immunotherapy
Capietto, A.-H., Jhunjhunwala, S., & Delamarre, L. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.007 · Cited by 66
Xue, G., Zheng, N., Fang, J., Jin, G., Li, X., Dotti, G., Yi, Q., & Lu, Y. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.011 · Cited by 66
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 69
The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction
Creech, A. L., Ting, Y. S., Goulding, S. P., Sauld, J. F. K., Barthelme, D., Rooney, M. S., Addona, T. A., & Abelin, J. G. (2018) · PROTEOMICS · doi:10.1002/pmic.201700259 · Cited by 65
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
Zhu, J., Liu, J.-Q., Shi, M., Cheng, X., Ding, M., Zhang, J. C., Davis, J. P., Varikuti, S., Satoskar, A. R., Lu, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98745 · Cited by 65
Son, S., Nam, J., Kim, A. S., Ahn, J., Park, K. S., Phoo, M. T., Sherren, B., Zou, W., Lee, S., Farokhzad, O. C., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00973-4 · Cited by 64
“Notably, Mann-NC therapy given without any antigen triggered tumour antigen-specific CD8 + and CD4 + T-cell responses, as shown by IFN-γ + ELISPOT assay with splenocytes restimulated with CT26-derived MHC-I-restricted gp70 AH-1 epitope 43 and MHC-II-restricted ME1 neo-epitope 44 , respectively (Fig.”
MethodMigration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses
Seyfizadeh, N., Muthuswamy, R., Mitchell, D. A., Nierkens, S., & Seyfizadeh, N. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.09.002 · Cited by 66
“…after ROCK lockade in the context of tissue inflammation likely due to the igh expression levels of integrin ligands such as ICAM-1 in LVs. his suggests that intralymphatic DC migration under uninflamed onditions is probably not integrin-mediated (Nitschké et al., 2012; ämmermann et al., 2008).”
Personalized cancer neoantigen vaccines come of age
Chu, Y., Liu, Q., Wei, J., & Liu, B. (2018) · Theranostics · doi:10.7150/thno.24387 · Cited by 64
“First, in 2015, their studies demonstrated that vaccination with a synthesized RNA vaccine resulted in the induction of potent tumour control in mice [39].”
BackgroundRoehle, K., Li, Q., Ventre, K. S., Heid, D., Ali, L. R., Lenehan, P. J., Heckler, M., Crowley, S. J., Stump, C. T., Ro, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5058 · Cited by 65
Deciphering the excited state behavior for 2-(4′-N,N-Dimethylaminophenyl)imidazo[4,5-b]pyridine
Zhao, J., Liu, X., & Zheng, Y. (2017) · Journal of Luminescence · doi:10.1016/j.jlumin.2017.03.056 · Cited by 62
Supabphol, S., Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1896702 · Cited by 64
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 66
“Furthermore, CD4 + T cells are increasingly recognized as both direct and indirect contributors to immunotherapeutic efficacy (3, 4, 58, 59).”
Azpilikueta, A., Agorreta, J., Labiano, S., Perez‐Gracia, J. L., Sánchez-Paulete, A. R., Aznar, M. A., Ajona, D., Bazo, I. G., Larráyoz, M., Teijeira, Á., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.013 · Cited by 64
Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes
Smith, C. C., Chai, S., Washington, A. R., Lee, S. J., Landoni, E., Field, K. P., Garness, J. A., Bixby, L. M., Selitsky, S. R., Parker, J. S., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0155 · Cited by 68
“Unlike murine preclinical models, where in vivo/ex vivo methods to further screen for immunogenicity can be applied (3, 15), no such benchtop prediction method for immunogenicity is currently available for humans.”
BackgroundSchuhmacher, J., Heidu, S., Balchen, T., Richardson, J. R., Schmeltz, C., Sonne, J., Schweiker, J., Rammensee, H., Straten, P. T., Røder, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001157 · Cited by 62
Landscape and selection of vaccine epitopes in SARS-CoV-2
Smith, C. C., Olsen, K. S., Gentry, K. M., Sambade, M., Beck, W., Garness, J., Entwistle, S., Willis, C., Vensko, S., Woods, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00910-1 · Cited by 65
Backlund, C. M., Holden, R. L., Moynihan, K. D., Garafola, D., Farquhar, C., Mehta, N. K., Maiorino, L., Pham, S., Iorgulescu, J. B., Reardon, D. A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204078119 · Cited by 61
Gu, Y., Yang, H. J., He, C., Zhao, T., Lu, R., Liu, J., Mo, X., Wen, F., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01479-4 · Cited by 62
“These mutation-generated epitopes (supplmentary Table S1) were selected from those immunogenic ones mined from CT26 tumor cells.(31) Mice were inoculated s.”
MethodA Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma
Tojjari, A., Saeed, A. M., Singh, M., Cavalcante, L. L., Şahin, İ. H., & Saeed, A. (2023) · Vaccines · doi:10.3390/vaccines11081357 · Cited by 69
“Ongoing research into DNA vaccines for HCC necessitates optimizing design, delivery methods, and adjuvant strategies to boost vaccine potency and elicit robust immune responses [53].”
BackgroundCancer Immunosurveillance by T Cells
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.08.001 · Cited by 58
Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
Meng, F., Li, L., Zhang, Z., Lin, Z., Zhang, J., Song, X., Xue, T., Xing, C., Liang, X., & Zhang, X. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12289 · Cited by 67
Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy
Kim, Y., Choi, J., Kim, E. H., Park, W., Jang, H., Jang, Y., Chi, S., Kweon, D., Lee, K., Kim, S. H., et al. (2024) · Advanced Science · doi:10.1002/advs.202309917 · Cited by 69
Nejo, T., Yamamichi, A., Almeida, N. D., Goretsky, Y. E., & Okada, H. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101385 · Cited by 64
Main Strategies for the Identification of Neoantigens
Gopanenko, A. V., Kosobokova, E. N., & Kosorukov, V. S. (2020) · Cancers · doi:10.3390/cancers12102879 · Cited by 63
Lam, H., McNeil, L. K., Starobinets, H., DeVault, V. L., Cohen, R. B., Twardowski, P. W., Johnson, M. L., Gillison, M. L., Stein, M. N., Vaishampayan, U. N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0377 · Cited by 66
“Both T cell subsets have clear importance in controlling tumor 61 growth (5,6).”
BackgroundWang, F., Xiao, W., Elbahnasawy, M. A., Bao, X., Zheng, Q., Gong, L., Zhou, Y., Yang, S., Fang, A., Farag, M. M. S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00980 · Cited by 60
Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy
Aktar, N., Yueting, C., Abbas, M., Zafar, H., Paiva‐Santos, A. C., Zhang, Q., Chen, T., Ahmed, M., Raza, F., & Zhou, X. (2022) · Journal of Oncology · doi:10.1155/2022/8901326 · Cited by 63
“Kreiter and colleagues [60] discovered that MHC-II preferentially binds mutant peptides rapidly and that CD4 T cells, the major immune response, identify particularly altered peptides in both colon cancer and breast cancer animal models.”
BackgroundAutoantigens as Partners in Initiation and Propagation of Autoimmune Rheumatic Diseases
Rosen, A., & Casciola-Rosen, L. A. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112205 · Cited by 62
Hartmaier, R. J., Charo, J., Fabrizio, D. A., Goldberg, M. E., Albacker, L. A., Pao, W. J., & Chmielecki, J. (2017) · Genome Medicine · doi:10.1186/s13073-017-0408-2 · Cited by 62
“Mutanome engineered RNA immunotherapy (MERIT) is an emerging technology that aims to create rapidly deployed, individualized, poly-neo-epitope mRNA vaccines [14].”
BackgroundCancer immunotherapy‐targeted glypican‐3 or neoantigens
Shimizu, Y., Suzuki, T., Yoshikawa, T., Tsuchiya, N., Sawada, Y., Endo, I., & Nakatsura, T. (2017) · Cancer Science · doi:10.1111/cas.13485 · Cited by 59
RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines
Shen, L., Zhang, J., Lee, H., Batista, M. T., & Johnston, S. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-50738-4 · Cited by 62
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy
Brightman, S. E., Naradikian, M. S., Miller, A. M., & Schoenberger, S. P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0220-603rr · Cited by 62
Self-citationArbelaez, C. A., Estrada, J., Gessner, M. A., Glaus, C., Morales, A. B., Mohn, D., Phee, H., Lipford, J. R., & Johnston, J. A. (2020) · npj Vaccines · doi:10.1038/s41541-020-00253-9 · Cited by 56
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade
Miyai, Y., Sugiyama, D., Hase, T., Asai, N., Taki, T., Nishida, K., Fukui, T., Chen-Yoshikawa, T. F., Kobayashi, H., Mii, S., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101230 · Cited by 59
“…helper T cells in tumor immunity and response to ICB (Zuazo et al, 2019; Kagamu et al, 2020; Li et al, 2020; Liu et al, 2020), which is distinct from their prominent role in inducing tumor-reactive cytotoxic T cells (Kreiter et al, 2015; Sahin et al, 2017; Borst et al, 2018; Zuazo et al, 2020).”
BackgroundMaine, C. J., Miyake-Stoner, S. J., Spasova, D. S., Picarda, G. G. A., Chou, A. C., Brand, E. D., Olesiuk, M. D., Domingo, C. C., Little, H. J., Goodman, T. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55843-9 · Cited by 62
Personalized approaches to active immunotherapy in cancer
Ophir, E., Bobisse, S., Coukos, G., Harari, A., & Kandalaft, L. E. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.07.004 · Cited by 66
de Groot, R., van Loenen, M. M., Guislain, A., Nicolet, B. P., Heeren, J. J. F., Verhagen, O. J. H. M., van den Heuvel, M. M., de Jong, J., Burger, P., van der Schoot, C. E., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1648170 · Cited by 61
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 61
Proteomic analysis of necroptotic extracellular vesicles
Shlomovitz, I., Erlich, Z., Arad, G., Edry‐Botzer, L., Zargarian, S., Cohen, H., Manko, T., Ofir‐Birin, Y., Cooks, T., Regev‐Rudzki, N., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04317-z · Cited by 65
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine
Galaine, J., Borg, C., Godet, Y., & Adotévi, O. (2015) · Vaccines · doi:10.3390/vaccines3030490 · Cited by 63
“Despite these limits, several epitopes derived from neoantigens are described [10,89–91] and neoepitopes derived from these mutations preferentially stimulate CD4 T cell responses [10].”
BackgroundDesigning string-of-beads vaccines with optimal spacers
Schubert, B., & Kohlbacher, O. (2016) · Genome Medicine · doi:10.1186/s13073-016-0263-6 · Cited by 56
“To improve the recovery of epitopes in SBVs, several groups have suggested the use of spacer sequences between epitopes [15–17] (Fig.”
BackgroundNew Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation
Curran, M. A., & Glisson, B. S. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-121900 · Cited by 61
A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
Tondini, E., Arakelian, T., Oosterhuis, K., Camps, M. G. M., van Duikeren, S., Han, W. G. H., Arens, R., Zondag, G. C. M., van Bergen, J., & OSSENDORP, F. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652539 · Cited by 61
“Differences in induction of T cell responses depending on the method of immunization have also been reported in RNA vaccination studies.(9) Why these differences between peptide and gene immunization occur is as yet not clear; however, considering the notion that some responses to tumor neoantigens can still be irrele…”
BackgroundComputational cancer neoantigen prediction: current status and recent advances
Fotakis, G., Trajanoski, Z., & Rieder, D. (2021) · Immuno-Oncology and Technology · doi:10.1016/j.iotech.2021.100052 · Cited by 54
“…only HLA class I molecules were considered to have an important role in neoantigen recognition, but there is increasing evidence that the majority of the immunogenic tumor mutanome is recognized by CD4 þ T cells, 89 and thus HLA class II neoantigens can also elicit immune responses to cancer.”
BackgroundGulbahce, N., Magbanua, M. J. M., Chin, R. G., Agarwal, M. R., Luo, X., Liu, J., Hayden, D. M., Mao, Q., Ciotlos, S., Li, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0688 · Cited by 57
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy
Tähtinen, S., Feola, S., Capasso, C., Laustio, N., Groeneveldt, C., Ylösmäki, E. O., Ylösmäki, L., Martins, B., Fusciello, M., Medeot, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2062 · Cited by 57
“(REGVELCPGNKYEMRRHGTTHSLVIHD)(13); the IEDB algorithm tool was used to predict the 144 exact epitope that binds H2Db and contains the single point mutation.”
MethodInfluentialmRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 58
The role of CD4+ T cells in tumor and chronic viral immune responses
Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 62
Optimized circular RNA vaccines for superior cancer immunotherapy
Yu, H., Wen, Y., Yu, W., Lu, L., Yu, Y., Liu, C., Hu, Z., Fang, Z., & Huang, S. (2024) · Theranostics · doi:10.7150/thno.104698 · Cited by 57
“…the therapeutic potential of the circRNA vaccines, we designed vaccines encoding a tandem of eight reported B16F10 tumor mutational neoantigens [44,45] (Figure 6A and Table S3) and an HPV E6E7 fusion protein vaccine [46] (Figure 7A and Table S3), and tested them in B16F10 and TC-1 tumor…”
Neoantigen Vaccines Pass the Immunogenicity Test
Linette, G. P., & Carreno, B. M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.007 · Cited by 57
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Lee, E. S., Shin, J. M., Son, S., Ko, H., Um, W., Song, S. H., Lee, J. A., & Park, J. H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801320 · Cited by 54
Brentville, V. A., Metheringham, R. L., Daniels, I., Atabani, S., Symonds, P., Cook, K. W., Vankemmelbeke, M., Choudhury, R., Vaghela, P., Gijon, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000560 · Cited by 54
Jain, K. K. (2020) · Medical Principles and Practice · doi:10.1159/000511107 · Cited by 55
Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning
Luo, J., Molbay, M., Chen, Y., Horvath, I., Kadletz, K., Kick, B., Zhao, S., Al-Maskari, R., Singh, I., Ali, M., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02528-1 · Cited by 53
“For Alexa Fluor 647–labeled EGFP mRNA LNPs, 20% non-labeled UTP was replaced by Alexa Fluor 647–labeled UTP 82,83 .”
Post-translational modifications such as citrullination are excellent targets for cancer therapy
Brentville, V. A., Vankemmelbeke, M., Metheringham, R. L., & Durrant, L. G. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101393 · Cited by 53
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.